AR007225A1 - Molecula mutante ctla4 soluble; proteina de fusion ctla4ig mutante soluble reactiva con el antigeno cd86 y proteina receptora ctla4 mutante soluble quela comprenden; codificacion de molecula de acido nucleico y cdna que la expresan; plasmido que comprende a este ultimo; metodo para producir una - Google Patents

Molecula mutante ctla4 soluble; proteina de fusion ctla4ig mutante soluble reactiva con el antigeno cd86 y proteina receptora ctla4 mutante soluble quela comprenden; codificacion de molecula de acido nucleico y cdna que la expresan; plasmido que comprende a este ultimo; metodo para producir una

Info

Publication number
AR007225A1
AR007225A1 ARP980100329A ARP980100329A AR007225A1 AR 007225 A1 AR007225 A1 AR 007225A1 AR P980100329 A ARP980100329 A AR P980100329A AR P980100329 A ARP980100329 A AR P980100329A AR 007225 A1 AR007225 A1 AR 007225A1
Authority
AR
Argentina
Prior art keywords
mutant
soluble
ctla4
protein
ctla4ig
Prior art date
Application number
ARP980100329A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR007225A1 publication Critical patent/AR007225A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Moléculas mutantes CTLA4 solubles que se enlazan con una rapidez superior a CD86 en comparación con el CTLA4Ig de la secuencia (I). Las moléculasmutantes CTLA4 solubles poseen una rapidez superior para CD86 respecto al CTLA4 tipo natural loc ual debería ser de mejor capacidad para bloquear laintroducción en células activadas por antígeno específico en comparación con CTLA4Ig. Proteínas de fusión de CTLA4Ig mutante soluble preferencialmentereactiva con el antígeno CD86 comparadas aCTL A4 de tipo natural, la proteína posee una primer secuencia de aminoácido que consiste del dominio extracelularde CTLA mutante y una segunda secuencia de aminoácido que consiste del punto de unión, regiones CH2 y CH3 de una inmunoglobulinahumana . Codificación demoléculas y ácido nucleico de secuencia de aminoácido que corresponde a moléculas mutantes CTLA4 solubles. En una de las modalidades de realización, lamolécula de ácido nucleico es un DNA (por ejemplo, cDNA) o unhíbrido del mismo. Un plásmido que comprende el cDNA. Un método para producir una proteínaque comprende el crecimiento de un sistema vector anfitrión para producir la proteína en el mismo y recuperar la proteína producida de este modo. Usodela moléc ula mutante CTLA4 soluble en un método para regular funcionalmente interacciones de CTLA4 y célula T CD28 positiva con CD86 y/o células positivasCD80.
ARP980100329A 1997-01-31 1998-01-26 Molecula mutante ctla4 soluble; proteina de fusion ctla4ig mutante soluble reactiva con el antigeno cd86 y proteina receptora ctla4 mutante soluble quela comprenden; codificacion de molecula de acido nucleico y cdna que la expresan; plasmido que comprende a este ultimo; metodo para producir una AR007225A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3659497P 1997-01-31 1997-01-31

Publications (1)

Publication Number Publication Date
AR007225A1 true AR007225A1 (es) 1999-10-27

Family

ID=21889481

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100329A AR007225A1 (es) 1997-01-31 1998-01-26 Molecula mutante ctla4 soluble; proteina de fusion ctla4ig mutante soluble reactiva con el antigeno cd86 y proteina receptora ctla4 mutante soluble quela comprenden; codificacion de molecula de acido nucleico y cdna que la expresan; plasmido que comprende a este ultimo; metodo para producir una

Country Status (17)

Country Link
US (2) US20030035816A1 (es)
EP (2) EP1557173A1 (es)
JP (1) JP2001510473A (es)
KR (1) KR20000070633A (es)
CN (1) CN1244803A (es)
AR (1) AR007225A1 (es)
AU (1) AU725016B2 (es)
BR (1) BR9806764A (es)
CA (1) CA2278771A1 (es)
HU (1) HUP0001971A3 (es)
IL (1) IL130656A0 (es)
NO (1) NO993708L (es)
NZ (1) NZ336009A (es)
PL (1) PL334898A1 (es)
RU (2) RU2235555C2 (es)
WO (1) WO1998033513A1 (es)
ZA (1) ZA98533B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
EP0892643B2 (en) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
AUPP221098A0 (en) * 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
CA2395945C (en) * 2000-01-03 2013-12-24 Tr Associates, L.L.C. Novel chimeric proteins and methods for using the same
AU6346601A (en) * 2000-05-26 2001-12-11 Bristol Myers Squibb Co Soluble ctla4 mutant molecules and uses thereof
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20020039577A1 (en) * 2000-06-09 2002-04-04 Townsend Robert M. Methods for regulating a lymphocyte-mediated immune response by blocking costimulatory signals and blocking LFA-1 mediated adhesion in lymphocytes
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
MXPA02012603A (es) * 2000-07-03 2003-05-14 Squibb Bristol Myers Co Metodos para tratamiento de enfermedades reumaticas utilizando una molecula de ctla4 soluble.
PL375139A1 (en) * 2001-01-26 2005-11-28 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
CZ305380B6 (cs) * 2001-05-23 2015-08-26 Bristol-Myers Squibb Company Léčivo pro inhibici rejekce transplantovaných buněk ostrůvků slinivky břišní
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
CA2482042A1 (en) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
JP4541157B2 (ja) * 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
US7332303B2 (en) * 2002-12-23 2008-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
JP2007501243A (ja) * 2003-08-04 2007-01-25 ブリストル−マイヤーズ　スクイブ　カンパニー 可溶性ｃｔｌａ４分子を用いる心臓血管疾患の治療方法
EP1684791A4 (en) 2003-10-27 2009-07-01 Amgen Inc COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE REACTION TO AN IMMUNOGENIC THERAPEUTIC AGENT
CA2836123C (en) 2005-12-20 2017-09-12 Bristol-Myers Squibb Company Compositions and methods for producing a composition
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
EP2385065A1 (en) * 2007-11-01 2011-11-09 Perseid Therapeutics LLC Immunosuppressive polypeptides and nucleic acids
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
EP2344540B1 (en) 2008-10-02 2017-11-29 Aptevo Research and Development LLC Cd86 antagonist multi-target binding proteins
CN102030828B (zh) * 2009-09-25 2014-10-29 上海抗体药物国家工程研究中心有限公司 一种高亲和力的CTLA4-Ig融合蛋白突变体
KR20130049775A (ko) 2010-03-12 2013-05-14 애브비 바이오테라퓨틱스 인크. Ｃｔｌａ４ 단백질 및 이의 용도
CA2812057A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
CA2003455C (en) * 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
CA2110518C (en) * 1991-06-27 2007-05-22 Peter S. Linsley Ctla4 receptor, fusion proteins containing it and uses thereof
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
EP0892643B2 (en) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20020039577A1 (en) * 2000-06-09 2002-04-04 Townsend Robert M. Methods for regulating a lymphocyte-mediated immune response by blocking costimulatory signals and blocking LFA-1 mediated adhesion in lymphocytes
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
MXPA02012603A (es) * 2000-07-03 2003-05-14 Squibb Bristol Myers Co Metodos para tratamiento de enfermedades reumaticas utilizando una molecula de ctla4 soluble.
PL375139A1 (en) * 2001-01-26 2005-11-28 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
CZ305380B6 (cs) * 2001-05-23 2015-08-26 Bristol-Myers Squibb Company Léčivo pro inhibici rejekce transplantovaných buněk ostrůvků slinivky břišní
JP4541157B2 (ja) * 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
US7332303B2 (en) * 2002-12-23 2008-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
JP2007501243A (ja) * 2003-08-04 2007-01-25 ブリストル−マイヤーズ　スクイブ　カンパニー 可溶性ｃｔｌａ４分子を用いる心臓血管疾患の治療方法

Also Published As

Publication number Publication date
WO1998033513A1 (en) 1998-08-06
NO993708D0 (no) 1999-07-30
ZA98533B (en) 1999-07-22
US20040014171A1 (en) 2004-01-22
NO993708L (no) 1999-09-28
RU2004115039A (ru) 2005-10-27
BR9806764A (pt) 2000-03-14
JP2001510473A (ja) 2001-07-31
NZ336009A (en) 2001-06-29
HUP0001971A3 (en) 2002-01-28
EP0988047A1 (en) 2000-03-29
AU6052598A (en) 1998-08-25
RU2235555C2 (ru) 2004-09-10
CN1244803A (zh) 2000-02-16
AU725016B2 (en) 2000-10-05
EP1557173A1 (en) 2005-07-27
HUP0001971A2 (hu) 2000-10-28
CA2278771A1 (en) 1998-08-06
PL334898A1 (en) 2000-03-27
IL130656A0 (en) 2000-06-01
EP0988047A4 (en) 2003-05-14
US20030035816A1 (en) 2003-02-20
KR20000070633A (ko) 2000-11-25

Similar Documents

Publication Publication Date Title
AR007225A1 (es) Molecula mutante ctla4 soluble; proteina de fusion ctla4ig mutante soluble reactiva con el antigeno cd86 y proteina receptora ctla4 mutante soluble quela comprenden; codificacion de molecula de acido nucleico y cdna que la expresan; plasmido que comprende a este ultimo; metodo para producir una
Sundkvist et al. Structure and function of free 40 S ribosome subunits: Characterization of initiation factors
HRP20240408T1 (hr) Inzulin-fc fuzijski proteini ultradugog djelovanja i metode uporabe
DE69636890D1 (de) Neuartige ctla4/cd28 liganden und deren anwendungen
DE68929507D1 (de) Rekombinante mykobakterielle expressions-träger sowie deren verwendung
ES2177475T1 (es) Genes de corynebacterium glutamicum que codifican proteinas de una ruta metabolica.
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
ATE455173T1 (de) Nucleinsäuremoleküle codierend ein verzweigungsenzym aus bakterien der gattung neisseria sowie verfahren zur herstellung von alpha-1,6-verzweigten alpha-1,4-glucanen
HUP9904239A2 (hu) Fehérjék nagymértékű expressziója
Winkel et al. Protein SYCP2 provides a link between transverse filaments and lateral elements of mammalian synaptonemal complexes
HUP0303843A2 (hu) CLyA-hemolizin alkalmazása proteinek exkretáltatására
CN102140476B (zh) 重组葡萄球菌蛋白a基因、含有该基因的表达载体及用途
DE69938722D1 (de) Verfahren zur herstellung von heterologen polypeptiden in trichothecene mangelmutanten filamentlösen pilzen
SG163592A1 (en) Methods and compositions for increasing longevity and protein yield from a cell culture
FR2812087B1 (fr) Procede de criblage de peptides utilisables en immunotherapie
WO2001073028A3 (en) A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
Yaneva et al. Isolation and properties of structured chromatin from Guerin ascites tumour and rat liver
DE60326449D1 (de) Chimere human papilloma virus 16 l1 proteine, welche ein l2 peptid enthalten, damit hergestellte virus-ähnliche partikel und methode zur herstellung der partikel
CN101709306B (zh) 含单链dna结合蛋白的融合蛋白及其表达和纯化的方法
ATE346919T1 (de) Nebenhoden-spezifisches rezeptorprotein und dessen verwendung
CN104672333A (zh) 一种人源ctla4融合蛋白及其制备方法和应用
ATE395422T1 (de) Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems
ATE196649T1 (de) Ein mutiertes crp-protein und verfahren und mittel zu dessen herstellung und verwendung
CN105601726B (zh) Oct4在调控IL-31基因表达中的应用
Qin et al. Genomic cloning, expression and recombinant protein purification of α and β subunits of the allophycocyanin gene (apc) from the cyanobacterium Anacystis nidulans UTEX 625

Legal Events

Date Code Title Description
FB Suspension of granting procedure